New Hope Against Breast Cancers That Spread to the Brain
By Dennis Thompson HealthDay Reporter
TUESDAY, Oct. 8, 2024 -- A recently approved targeted chemotherapy drug can significantly extend the lives of advanced breast cancer patients who have developed tumors in their brains, new clinical trial results show.
On average, patients receiving the drug Enhertu (trastuzumab deruxtecan) survived more than 17 months without any progression of their cancer, researchers reported Oct. 4 in the journal Nature Medicine.
More than 60% of patients survived 12 months without further tumor growth, results show.
And in those patients who’d developed brain tumors, more than 70% had their tumors shrink and 90% were alive a year after the start of their treatment, researchers found.
“These findings offer hope to patients with brain metastases in particular,” said co-lead researcher Dr. Nadia Harbeck, director of the breast cancer clinic at Ludwig-Maximilians University of Munich in Germany.
The U.S. Food and Drug Administration approved Enhertu in April for treatment of people with advanced HER2-positive cancers.
HER2 (human epidermal growth factor 2) is a protein that can promote the growth and spread of breast cancer. HER2-positive breast cancers account for up to 20% of all breast cancers, researchers said in background notes.
Enhertu contains trastuzumab and deruxtecan.
Trastuzumab is a monoclonal antibody that targets and attaches to HER2 proteins on a cancer cell. This allows deruxtecan -- a chemo drug -- to enter the cancer cell and kill it off, along with other tumor cells nearby.
“This is why we can use this active ingredient in the first place,” Harbeck said i a university news release. “Otherwise, it would be much too toxic.”
For this new clinical trial, researchers recruited more than 500 HER2-positive breast cancer patients, including 263 whose cancer had spread to their brain. These patients came from 78 cancer centers around the world.
The study was sponsored by the drug companies AstraZeneca and Daiichi Sankyou, which developed and market Enhertu.
Sources
- Ludwig-Maximilians University of Munich, news release, Oct. 4, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
A Saliva-Based Test for Breast Cancer Might Be Near
MONDAY, Aug. 4, 2025 — In a small new study, a handheld saliva-sampling device successfully detected breast cancer 100% of the time, researchers said. The study only...
Palliative Care or Hospice? What's the Distinction?
SATURDAY, July 26, 2025 — If a doctor diagnoses you with a serious illness and suggests palliative care, don’t jump to conclusions. It doesn’t mean you have...
For the Win: College Student Powerlifts Past Breast Cancer
FRIDAY, July 25, 2025 — LaShae Rolle, 27, is a competitive powerlifter capable of squatting 441 pounds, benching 292 pounds and deadlifting 497 pounds. Last year, breast...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.